Compare BOH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | EWTX |
|---|---|---|
| Founded | 1897 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | 2021 |
| Metric | BOH | EWTX |
|---|---|---|
| Price | $73.77 | $30.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $80.40 | $36.00 |
| AVG Volume (30 Days) | 422.7K | ★ 704.0K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.66 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.45 | $10.60 |
| 52 Week High | $80.61 | $31.82 |
| Indicator | BOH | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 59.52 |
| Support Level | $65.63 | $28.56 |
| Resistance Level | $79.43 | $31.12 |
| Average True Range (ATR) | 2.49 | 1.42 |
| MACD | -0.73 | -0.12 |
| Stochastic Oscillator | 18.04 | 82.79 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.